Tucidinostat (Chidamide)

For research use only. Not for use in humans.

目录号：S8567 别名： HBI-8000, CS-055

Tucidinostat (Chidamide) Chemical Structure

CAS No. 1616493-44-7

Tucidinostat (Chidamide, HBI-8000, CS-055) 是HDAC1, 2, 3, 10的低摩尔浓度抑制剂，IC50分别为95、160、67、78 nM。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 794.43	现货
5mg	RMB 795.33	现货
25mg	RMB 2023.28	现货
100mg	RMB 5299.86	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Tucidinostat (Chidamide)发表文献8篇：

Biomed Pharmacother, 2021, 138:111485

PubMed: 33740521 ( click the link to review the publication )

SLAS Discov, 2021, 24725552211002463

PubMed: 33783263 ( click the link to review the publication )

Exp Ther Med, 2021, 21(5):515

PubMed: 33815588 ( click the link to review the publication )

Eur J Med Chem, 2021, 215:113169

PubMed: 33588178 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0336

PubMed: 32978226 ( click the link to review the publication )

Eur J Med Chem, 2020, 15;196:112291

PubMed: 32325365 ( click the link to review the publication )

Front Oncol, 2020, 10:563666

PubMed: 33014881 ( click the link to review the publication )

HIV Med, 2020, 21(11):747-757

PubMed: 33369029 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

Tucidinostat (Chidamide, HBI-8000, CS-055) 是HDAC1, 2, 3, 10的低摩尔浓度抑制剂，IC50分别为95、160、67、78 nM。

靶点

HDAC3 ^[1] (Cell-free)	HDAC10 ^[1] (Cell-free)	HDAC1 ^[1] (Cell-free)	HDAC2 ^[1] (Cell-free)
67 nM	78 nM	95 nM	160 nM

体外研究

Chidamide抑制I型HDACs 1-3，以及IIb型HDAC10。在人类宫颈腺癌Hela细胞和人源PBMC细胞中，Chidamide显著地诱导组蛋白H3乙酰化。在微摩尔浓度范围内，Chidamide和MS-275可抑制大多数人源肿瘤细胞系的细胞生长，但并不是所有所检测的肿瘤细胞（共检测18种）。在人胚肾（CCC-HEK）和人胚肝（CCC-HEL）中，Chidamide对正常细胞的毒性作用比MS-275大大减少，说明Chidamide对正常细胞和癌细胞的细胞毒性作用的差异^[1]。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
Sf9	NVuzZYhWTnWwY4Tpc44h[XO\|YYm=		NVn0RmhpPSCvaX7z	Mom1TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDISGFEOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDibY91cW67bHH0[YQhdHm\|aX7lJFkh[WOndInsZZRm\CCqaYP0c45mKEh\|IDixJJRwKDJzIILld4llfWW\|KTDhd{B{fWK\|dILheIUhcW6ldXLheIVlKG[xcjC1JI1qdnNiZn;scI94\WRiYomgd5Vje3S{YYTlJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IE[wJI1qNCCLQ{WwJF0hOC5zMUKg{txONg>?	NHXsNZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVc6Pyd-Mki4N\|U4QTd:L3G+
EBC1	MWXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnHEO\|IhcHK\|	NYfCb5Q5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCyMlkh\|ryPLh?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh\|NUe5O{c,Ojh6M{W3PVc9N2F-
HCT116	NF\xTmdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWrS[3M{PzJiaILz	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iNz64JO69VS5?	NXzFV5BoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N\|U4QTdpPkK4PFM2Pzl5PD;hQi=>
HL60	M{\jUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV;IbItrPDhiaILz	MnzlS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGw3OCClZXzsd{BqdmO3YnH0[YQh\m:{IES4JIhzeyCkeTDNWHMhdWW2aH;kMEBIUTVyIE2gNE41KM7:TT6=	Mlu1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|YzOTl6OD:nQmNpTU2ETEyvZV4>
Jurkat	MonLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkPTOFghcHK\|	MUjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDKeZJs[XRiY3XscJMhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRUKG2ndHjv[EwhT0l3MDC9JFEvPSEQvF2u	NV7MeGlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
hematopoietic malignant cells	M{W2SGN6fG:2b4jpZ4l1gSCjc4PhfS=>			MmPlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gbIVu[XSxcH;p[ZRq[yCvYXzp[45idnRiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25uIFfJOVAhRSBzLki2JO69VS5?	NIS1PIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
U2OS	M2jJPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYq0PEBpenN?	NVO4[XBIT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXTKRUzDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNibXX0bI9lNCCJSUWwJF0hOiEQvF2u	M1LhWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK\|5EcEWPQly8M4E,
HepG2	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXnodlB4PDhiaILz	NGPnb4lIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJ\XCJMjDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNibXX0bI9lNCCJSUWwJF0hPCEQvF2u	NHvDbnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
LNCAP	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3P3fFQ5KGi{cx?=	M2j6UGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGxPS0GSIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK\|IHL5JG1VWyCvZYToc4QtKEeLNUCgQUA1KM7:TT6=	NVnFcFhURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
Raji	NGnnR4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHfj[2Y1QCCqcoO=	NH6wdXdIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBT[WqrIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK\|IHL5JG1VWyCvZYToc4QtKEeLNUCgQUA1KM7:TT6=	Mmq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|YzOTl6OD:nQmNpTU2ETEyvZV4>
MCF7	NGjCOY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4jMSFQ5KGi{cx?=	NYeybWlJT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNibXX0bI9lNCCJSUWwJF0hPSEQvF2u	NGOzS2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
28SC	NGnUTlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXm0PEBpenN?	NH;PWpNIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckAzQFOFIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK\|IHL5JG1VWyCvZYToc4QtKEeLNUCgQUA2NjhizszNMi=>	MoflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|YzOTl6OD:nQmNpTU2ETEyvZV4>
PANC1	MonQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mk\2OFghcHK\|	NYTqOJd7T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEGQQ{GgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSVIH3leIhw\CxiR1m1NEA:KDZwMzFOwG0v	NE\hWXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
human solid tumor cells	MWLDfZRwfG:6aXPpeJkh[XO\|YYm=			NFixdJdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckB{d2yrZDD0eY1weiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdixiR1m1NEA:KDZwNkWg{txONg>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
HeLa	NUHOSG9YTnWwY4Tpc44h[XO\|YYm=		M{nRblExKG2rboO=	M{XKTGlvcGmkaYTpc44hd2ZiSFTBR{Bmdnq7bXH0bYMh[WO2aY\peJkhcW5iaIXtZY4hUGWOYTDj[YxteyCrbnP1ZoF1\WRiZn;yJFExKG2rboOgbY4heHKnc3XuZ4Uhd2Zic4Xid5Rz[XSnIHL5JINwdG:{aX3leJJq[yCjY4Tpeol1gSCjc4PhfUwhUUN3MDC9JFcvOiEQvF2u	Ml\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|YzOTl6OD:nQmNpTU2ETEyvZV4>
MDA-MB-231	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4T5S\|Q5KGi{cx?=	M2Dhc2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliTWTTJI1mfGixZDygS2k2OCB;IEeuPUDPxE1w	NVi4S2xpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
SMMC7721	M2LlW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MoTPOFghcHK\|	NG\PR\|VIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUVU2FN{eyNUBk\WyuczDpcoN2[mG2ZXSg[o9zKDR6IHjyd{BjgSCPVGOgcYV1cG:mLDDHTVUxKD1iMU[g{txONg>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
DU145	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4G5eVQ5KGi{cx?=	MX7Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{BqdmO3YnH0[YQh\m:{IES4JIhzeyCkeTDNWHMhdWW2aH;kMEBIUTVyIE2gNlUh\|ryPLh?=	NUjBVotQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
HeLa	M1LiVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFm2fVM1QCCqcoO=	M2HQTmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhmVGFiY3XscJMhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRUKG2ndHjv[EwhT0l3MDC9JFQxKM7:TT6=	NYPW[Ww5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
U2OS	MlvjSpVv[3Srb36gZZN{[Xl?	NWnZVXY3OSC3TR?=	MmfQNlQhcHK\|	M1XIPWFkfGm4YYTpc44hd2ZiUGDBVmchMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hXTKRUzDj[YxteyCjdDCxJJVOKGmwIIDy[ZNmdmOnIH;mJFExKHWPIILvd4lodGm2YYrvcoUhcW6ldXLheIVlKG[xcjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6	MmLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|YzOTl6OD:nQmNpTU2ETEyvZV4>
U2OS	NGXhOpZHfW6ldHnvckBie3OjeR?=	MkK4NUB2VQ>?	MoXBNlQhcHK\|	M2DtZ2FkfGm4YYTpc44hd2ZiRWLi[ZRiKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHj1cYFvKFV{T2OgZ4VtdHNiYYSgNUB2VSCrbjDwdoV{\W6lZTDv[kAxNjBzIIXNJGUzKGmwY4XiZZRm\CCob4KgNlQhcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	M1;IW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK\|5EcEWPQly8M4E,
U2OS	MYPGeY5kfGmxbjDhd5NigQ>?	MXmxJJVO	M{nmWlI1KGi{cx?=	NGH4[IJC[3SrdnH0bY9vKG:oIHfseYxkd2OxcoTpZ49q\CC{ZXPldJRweiBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDoeY1idiCXMl;TJINmdGy\|IHH0JFEhfU1iaX6gdJJme2WwY3Wgc4YhOC5zIIXNJIRmgGGvZYToZZNwdmViaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7	MnPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|YzOTl6OD:nQmNpTU2ETEyvZV4>
U2OS	NXvz[5M5TnWwY4Tpc44h[XO\|YYm=	M3nMfVEhfU1?	MWKyOEBpenN?	NYDsW5p{SWO2aY\heIlwdiCxZjDFVoFteGijIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJIh2dWGwIGWyU3Mh[2WubIOgZZQhOSC3TTDpckBxemW\|ZX7j[UBw\iByLkCxJJVOKEV{IHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?=	NUL3V4hyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
U2OS	MnTpSpVv[3Srb36gZZN{[Xl?	MoHGNUB2VQ>?	MW[yOEBpenN?	M4e5SWFkfGm4YYTpc44hd2ZiZ3z1cINw[2:{dHnjc4llKHKnY3XweI9zKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHj1cYFvKFV{T2OgZ4VtdHNiYYSgNUB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl?	NEK5V\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
U2OS	MkHOSpVv[3Srb36gZZN{[Xl?	MWixJJVO	NILleIQzPCCqcoO=	MYfBZ5RqfmG2aX;uJI9nKFCSQWLHJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKGi3bXHuJHUzV1NiY3XscJMh[XRiMTD1UUBqdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk>	NUnXfYdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
U2OS	MVTGeY5kfGmxbjDhd5NigQ>?	MUCxJJVO	NWH3e4JHOjRiaILz	MXPBZ5RqfmG2aX;uJI9nKEWUYXzwbIEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hXTKRUzDj[YxteyCjdDCxJJVOKGmwY4XiZZRm\CCob4KgNlQhcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>?	NF35OlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
U2OS	MXrGeY5kfGmxbjDhd5NigQ>?	MXexJJVO	MVqyOEBpenN?	M3PtZWFkfGm4YYTpc44hd2ZiRWLi[ZRiKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHj1cYFvKFV{T2OgZ4VtdHNiYYSgNUB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl?	M2frcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK\|5EcEWPQly8M4E,

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; PubMed: 30854137 J Cancer Expression and activation level of Caspase-3 and PARP after treatment of serial dilutions of chidamide in HCC827 cells (48h). p-EGFR / EGFR / p-STAT3 / STAT3 / p-AKT / AKT / p-AMPK / MAPK ; PubMed: 30854137 J Cancer Chidamide inhibition of PTK signaling molecules in A549 cells (48h). Ace-H3K18 / Ace-H3K9 / Ac-H4K8 ; PubMed: 29773595 Haematologica Western blot analysis of H3 acetylation at Lys18 and Lys9 and H4 acetylation at Lys8. H3 and H4 expression levels were used as loading controls. Mcl-1 / Myc / Bcl-xl / p21 / p27 / CDK6 / CDK4 / Cyclin D2 ; PubMed: 29773595 Haematologica Western blot analysis of Mcl-1, Myc, Bcl-xL, Bcl-2, p21, p27, CDK4, CDK6, and Cyclin-D2 levels; α-tubulin was used as the loading control. HDAC1 / HDAC2 / HDAC3 / acetyl-H3 / acetyl-H4 ; PubMed: 31289512 Oncol Lett (A) RPMI8226 cells were treated with 0, 0.5, 1 or 2 µmol/l chidamide for 48 h and (B) U266 cells were treated with 0, 2, 4 or 8 µmol/l chidamide for 48 h, and HDACs expression was assessed using western blot analysis.	30854137 29773595 31289512
Growth inhibition assay	Cell viability; PubMed: 29100410 Oncotarget (a) Proliferation rates at 24, 48, 72 hour of Hs445 cells after treated with 0.1μM, 0.3μM, 1μM, 3μM, 10μM, 30μM Chidamides; (b) proliferation rates at 24, 48, 72 hours of L428 cells after treated with 0.1μM, 0.3μM, 1μM, 3μM, 10μM, 30μM Chidamide;	29100410

体内研究

在小鼠结肠癌HCT-8移植瘤模型中，Chidamide具有体内抗肿瘤活性。给药浓度范围为12.5-50 mg/kg的Chidamide可浓度依赖性地减少肿瘤大小和重量。Chidamide的给药浓度为50 mg/kg时，相较于对照药物组5-FU（20 mg/kg）和MS-275组（25 mg/kg）具有相似甚至更大的功效。在携瘤动物模型中，Chidamide耐受良好^[1]。

细胞实验： ^[1]	- 合并 Cell lines: PBMC效应细胞 Concentrations: 0-400 nM Incubation Time: 24-72 h Method: 将分离的PBMC效应细胞接种于6孔板（细胞密度为6 x 10⁶ cells/孔），用不同浓度的chidamide(0-400 nM)处理细胞一定时间（24-72 h）。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: Athymic nude mice (BALB/c-nu) Dosages: 12.5-50 mg/kg Administration: oral (Only for Reference)

参考文献

[1] Ning ZQ, et al. Cancer Chemother Pharmacol. 2012, 69(4):901-9.

溶解度 (25°C)

体外	DMSO	78 mg/mL (199.78 mM)
	Ethanol	2 mg/mL (5.12 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 1% CMC Na	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Tucidinostat (Chidamide) SDF

分子量	390.41
化学式	C₂₂H₁₉FN₄O₂
CAS号	1616493-44-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	HBI-8000, CS-055

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04651127	Recruiting	Drug: Toripalimab + Chidamide	Cervical Cancer\|Cervix Cancer\|Cervix Neoplasm	Sun Yat-sen University	November 9 2020	Phase 1\|Phase 2
NCT03820596	Recruiting	Drug: Sintilimab\|Drug: Chidamide	Safety and Efficacy	Huiqiang Huang\|Sun Yat-sen University	March 29 2019	Phase 1\|Phase 2
NCT02944812	Unknown status	Drug: Chidamide	Peripheral T Cell Lymphoma	Guangdong Provincial People''s Hospital	March 2016	Phase 2
NCT02569489	Withdrawn	Drug: HBI-8000\|Drug: Trastuzumab\|Drug: Paclitaxel	Breast Cancer	HUYA Bioscience International	December 2015	Phase 1
NCT02513901	Completed	Drug: Chidamide	Chronic HIV Infections	Tang-Du Hospital\|Chipscreen Biosciences Ltd.	August 2015	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

研究领域

产品类型

定制您的化合物库

Tucidinostat (Chidamide)

客户使用Selleck生产的Tucidinostat (Chidamide)发表文献8篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Tucidinostat (Chidamide) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

技术支持

HDAC Signaling Pathway Map

相关HDAC产品